Advancing TB Vaccines for the World
|
|
- Lee Armstrong
- 6 years ago
- Views:
Transcription
1 Advancing TB Vaccines for the World
2 Aeras Leadership EXECUTIVE STAFF Jacqui Shea, PhD Chief Executive Officer Ann Ginsberg, MD, PhD Chief Medical Officer BOARD MEMBERS Lota S. Zoth, CPA (Chair) Former CFO of MedImmune, Inc. Aeras is a nonprofit biotechnology organization developing new, effective tuberculosis (TB) vaccines that are affordable and accessible to all who need them. Aeras works through partnerships in both the public and private sectors, with individuals, research organizations, academic institutions, funders, policymakers and other stakeholders around the world to advance TB vaccine science and development. Founded in 1997 as a U.S. 501(c)(3) nonprofit biotechnology organization Offices in Rockville, USA (HQ); Cape Town, South Africa; Beijing, China Governed by an independent Board of Directors, with external technical advisory groups incorporating global expertise Executive leadership team with decades of experience developing and commercializing new vaccines and biologics Barry Bloom, PhD Distinguished Service Professor at Harvard University David L. Blumberg, MBA Former Life Sciences Sector Leader of KPMG Jim Connolly Former President & CEO of Aeras Marja Esveld, MSc Senior Advisor, Global Health and Innovation Marian Eslie Jacobs, MD Former Dean, Faculty of Health Sciences, University of Cape Town Professor Michel Kazatchkine, MD Senior Fellow, Global Health Programme, Graduate Institute of International and Development Studies Wayne F. Pisano President and CEO, VaxInnate Regina Rabinovich, MD, MPH Exxon Mobil Malaria Scholar in Residence, Harvard School of Public Health Jacqueline E. Shea, PhD CEO of Aeras Gerd Zettlmeissl, PhD Former CEO of Intercell AG
3 Building support to solve a global crisis Surveillance data for 2016 showed that TB killed more people than any other infectious disease in the world. With 10.4 million new cases and 1.7 million deaths, TB was more deadly than Ebola, malaria, or even HIV. 1 We will not eliminate TB with the current vaccine and vaccination strategies available. In fact, the World Health Organization s End TB Strategy states that a new TB vaccine is essential to ending the TB epidemic. 2 A new vaccine will also be critical in the fight against antimicrobial resistance (AMR). If left unchecked, by 2050 AMR will kill 10 million people and a quarter of those deaths will come from drug resistant TB. 3 These statistics are staggering, but we know there is hope: A widely used, more effective TB vaccine would be the single most costeffective tool in mitigating this epidemic and would make a major impact on efforts to control AMR. 3 5 Aeras is working diligently to build coalitions among stakeholders, raise awareness with governments across the globe, and move TB vaccine research into the forefront of global health discussions. Deaths in 2016 TB 1.7 million Coinfection (TB and HIV/AIDS) 400,000 HIV/AIDS 1 million 1
4 Innovating to ultimately end TB Together with our partners, Aeras is successfully advancing TB vaccine science. Moving promising vaccines into clinical trials Global clinical pipeline of tb vaccine candidates Viral Vector Protein/Adjuvant Mycobacterial Whole Cell or Extract Mycobacterial Live Fifteen years ago, there was only one vaccine candidate in the clinical trial pipeline. Since then, Aeras has helped develop 9 TB vaccine candidates and conducted over 35 Phase 1-2b clinical trials. Of the 12 vaccine candidates currently in human clinical trials globally, four are supported by Aeras. We expect results from two current clinical trials in the first half of 2018: The first is evaluating the ability of Sanofi Pasteur vaccine candidate H4:IC31 and BCG to prevent sustained infection (POI) in adolescents in a high TB-burden setting. POI is a new study design that can be used to evaluate the biologic effect of a candidate before advancing to larger, longer and more costly prevention of disease studies. Primary results from another novel late-stage clinical trial for GSK vaccine candidate M72/AS01E testing prevention of disease are expected to follow. Phase 1 MTBVAC Biofabri, TBVI, Zaragoza Ad5 Ag85A McMaster, CanSino ChAdOx1.85A/MVA85A (ID/IM/Aerosol) Univ of Oxford Phase 2a RUTI Archivel Farma, S.L H56: IC31 SSI, Valneva, Aeras H4: IC31 Sanofi Pasteur, SSI, Aeras ID93 + GLA-SE IDRI, Wellcome Trust TB/FLU-04L RIBSP Continuing to explore a diverse range of vaccine candidate types will be critical to success since scientists don t yet fully understand what type of immune response will protect people from TB. Each study conducted offers an unprecedented opportunity to apply learnings to optimize TB vaccine development. 2
5 Phase 2b Phase 3 DAR-901 VaccaeTM Dartmouth, GHIT Anhui Zhifei Longcom M72 + AS01E GSK, Aeras VPM 1002 SII, Max Planck, VPM, TBVI (Phase 2/3) 3
6 Advancing the understanding and speed of TB vaccine science Aeras follows globally developed criteria for selecting, assessing and advancing only the most promising vaccine candidates through the research and development pipeline, which helps ensure the best stewardship of the limited funds available for TB vaccine development. Further steps taken by Aeras to accelerate vaccine development include: The AerasSHARE Biorepository, launched in September 2016, which allows investigators from the broader research community to access clinical specimens collected by Aeras and its research partners in an effort to facilitate state-of-the-art TB vaccine science and promote world-wide collaboration among researchers. Incorporation of the latest data within TB vaccine research and development (R&D) stage gate criteria. These criteria, developed with the TuBerculosis Vaccine Initiative (TBVI), help inform and align vaccine developers on the key steps in TB vaccine development. Creation of improved animal models of disease to facilitate and enhance initial screening for promising TB vaccine candidates. We also worked with partners to initiate the R&D program to develop a controlled human infection model for TB, which has evolved to the Human Challenge Consortium with support from the Bill & Melinda Gates Foundation. Co-organizing the biennial Global Forum on TB Vaccines, which brings the global TB vaccine field together to accelerate progress. 4
7 Building clinical trial capacity in high-burden countries for lasting impact Aeras fosters knowledge sharing and research capacity strengthening in multiple countries with a high TB burden. The value of collaborating with Aeras goes beyond the immediate benefits of successful TB vaccine research. Aeras has helped establish and support clinical research capacity throughout Africa, including trial sites in South Africa, Tanzania, and Zambia. Collateral benefits to clinical trial sites include equipment and facilities, skills development, high-quality jobs for local researchers, healthcare workers and other staff, and generally a higher standard of healthcare for trial participants. And Aeras worked with the AIDS Vaccine Advocacy Coalition, clinical trial site staff, community advisory boards, TB Alliance and Treatment Action Group to draft Good Participatory Practice Guidelines for TB vaccine clinical trials. 5
8 Advocating for resources to match the scale of the problem TB research and development is significantly underfunded. Investments in TB vaccine R&D have averaged $95 million per year over , less than half of the $250 million per year needed to advance TB vaccines. 6 Aeras advocates for an expanded and diversified funding base to help ensure long-term financial support for urgently needed TB vaccine research and development. We know that new, effective vaccines are both essential to the fight against TB and ultimately achievable but only with sustained global investment and support. number of deaths in 2016 Amount of research & Development Investment TB 1.7 million $95.4 million HIV 1 million $894 million Ebola 11,310 for the entire outbreak up to 2016 $244.6 million from start of outbreak REFERENCES 1. WHO. Global Tuberculosis Report (World Health Organization, 2017). 2. WHO. The End TB Strategy Factsheet. (2015). Available at: (Accessed: 9th September 2016) 3. The Review on Antimicrobial Resistance. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. (2016). 4. Harris, R. C., Sumner, T., Knight, G. M. & White, R. G. Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines. Hum. Vaccines Immunother. 12, (2016). 5. World Bank. Drug-Resistant Infections: A Threat to Our Economic Future (Discussion Draft). (World Bank, 2016). 6. TAG Report on Tuberculosis Research Funding Trends, : The Ascent Begins. (Treatment Action Group, 2017). aeras.org
Urgent Need for Global Investment in TB Vaccines. Stop TB Partnership Board Meeting Jacqueline E. Shea, PhD Chief Executive Officer Aeras
Urgent Need for Global Investment in TB Vaccines Stop TB Partnership Board Meeting Jacqueline E. Shea, PhD Chief Executive Officer Aeras 2 We need a more effective vaccine than BCG 3 Global Strategies
More informationTB Vaccine Development Strategy Overview
TB Vaccine Development Strategy Overview October 28, 2014 Angeline Nanni, MBA, MS Aeras Director, Global Access TB is Mother Nature s number one killer over the past centuries TB is spread through the
More informationTB Vaccine Research and Development: Progress, Strategies and Controversies
15 March 2016 GVIRF Global Forum Johannesburg, South Africa TB Vaccine Research and Development: Progress, Strategies and Controversies Lewis Schrager, M.D. V.P., Scientific Affairs Rockville, MD USA Source:
More informationDeveloping TB Vaccine Clinical Trial Capacity Aeras Perspective. Vicky Cardenas, PhD, JD
Developing TB Vaccine Clinical Trial Capacity Aeras Perspective Vicky Cardenas, PhD, JD ASEAN-EU STI Days 21-23 January 2014 Aeras Founded in 2003 Mission: Develop improved TB vaccines that are affordable
More informationTuberculosis The Race for a Cure
Tuberculosis The Race for a Cure Kari Stoever Faster Cures Annual Conference November 4, 2013 Aeras: A non profit biotech advancing TB vaccines for the world Founded in 2003 in-house capabilities in finance,
More informationUpdate on Tuberculosis Vaccines
March 27, 2014 Update on Tuberculosis Vaccines - 2014 Tom Evans MD CEO, Aeras TB is Mother Nature s AERAS GLOBAL number TB VACCINE one FOUNDATION killer over the past centuries TB is spread through the
More informationTB Vaccine Development Status: Review of Critical Issues and Selected Candidates in Phase 2 or Phase 3
TB Vaccine Development Status: Review of Critical Issues and Selected Candidates in Phase 2 or Phase 3 22 June 2017 WHO PD-VAC Geneva, Switzerland Lewis K. Schrager, M.D. North Bethesda, MD USA Outline
More informationNew Tools in the Post-UNHLM. David Lewinsohn StopTB Partnership New Tools Working Groups
New Tools in the Post-UNHLM David Lewinsohn StopTB Partnership New Tools Working Groups Ending TB Guiding Principles TB elimination not achievable without new tools While tools not widely available in
More informationPress Release: Embargo in place until Monday, February 19 th, 2018 I 6:00 Eastern standard Time (11GMT)
Press Release: Embargo in place until Monday, February 19 th, 2018 I 6:00 Eastern standard Time (11GMT) Results from innovative tuberculosis vaccine trial show potential for new BCG revaccination strategies
More informationGlobal Report on Tuberculosis Vaccines 2018
Global Report on Tuberculosis Vaccines 2018 Executive Summary EDCTP Acknowledgements The Global Report on Tuberculosis Vaccines 2018 is prepared at the request of the Global TB Vaccine Partnership (GTBVP)
More informationLetter from the CEO. Dear Friends of IAVI,
IAVI Annual Report 2017 Letter from the CEO Dear Friends of IAVI, We are pleased to present an overview of the progress IAVI and partners have made in 2017 toward our pursuit of the development of vaccines
More informationUpdate: Working Group on New Vaccines. David Lewinsohn Chair, Working Group on New Vaccines
Update: Working Group on New Vaccines David Lewinsohn Chair, Working Group on New Vaccines The Stop TB Partnership Global Partners' Forum Global TB Drug Facility GLC Coordinating Board Partnership Secretariat
More informationENHANCING AFRICA S PUBLIC HEALTH RESPONSE THROUGH INNOVATION AND PARTNERSHIPS
ENHANCING AFRICA S PUBLIC HEALTH RESPONSE THROUGH INNOVATION AND PARTNERSHIPS Strategic plan for the Africa CDC March 24-25, 2017 The Ebola outbreak underscored the fact that 2 pandemics are not just a
More informationACHAP LESSONS LEARNED IN BOTSWANA KEY INITIATIVES
ACHAP Together with our company s foundation, a U.S.-based, private foundation, and the Bill & Melinda Gates Foundation, we established the African Comprehensive HIV/AIDS Partnerships (ACHAP) in 2000 to
More informationPartnerships in TB Vaccine Research & Development. James E. Connolly President & CEO Aeras Global TB Vaccine Foundation
Partnerships in TB Vaccine Research & Development James E. Connolly President & CEO Aeras Global TB Vaccine Foundation Aeras Mission & GLOBAL the TB VACCINE PDP FOUNDATION Model Develop new, more effective
More informationInnovation, Access and Delivery for Universal Health Coverage
A side event at the UHC Forum Co-hosted by UNDP and the GHIT Fund Tokyo, Japan 12 December 2017 Innovation, Access and Delivery for Universal Health Coverage From Innovation & Inequality, a UNDP-supported
More informationMODULE SIX. Global TB Institutions and Policy Framework. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE SIX Global TB Institutions and Policy Framework Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be Covered Global TB policy and coordinating structures The Stop TB Strategy TB/HIV collaborative
More informationSuraj Madoori, Treatment Action Group, U.S. and Global Health Policy Director. On behalf of the Tuberculosis Roundtable
United States House of Representatives Committee on Appropriations Subcommittee on State and Foreign Operations and Related Programs Fiscal Year 2020 Written Testimony Suraj Madoori, Treatment Action Group,
More informationJOINING FORCES COLLABORATING WITH PARTNERS Annual Report
2016 Annual Report JOINING FORCES COLLABORATING WITH PARTNERS As a product development partnership, TB Alliance works with a wide variety of partners to advance TB drug development in the most efficient
More informationOkinawa, Toyako, and Beyond: Progress on Health and Development
Okinawa, Toyako, and Beyond: Progress on Health and Development Prof. Michel D. Kazatchkine Executive Director The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations University, Tokyo,
More informationFifth Global Forum on TB Vaccines
Media coverage Fifth Global Forum on TB Vaccines The Hindi http://www.thehindu.com/sci-tech/health/experts-urge-more-funds-to-tackle-tuberculosiscrisis/article22809370.ece HEALTH Experts urge more funds
More informationBetter Diagnostics for Tuberculosis: A Bolder Vision for TB Control. Peter M. Small, MD Senior Program Officer
Better Diagnostics for Tuberculosis: A Bolder Vision for TB Control Peter M. Small, MD Senior Program Officer peter.small@gatesfoundation.org June 21, 2010 Disclosure No financial/industry conflicts Patent
More informationSPONSORSHIP OPPORTUNITIES JUNE 12-13, umanitoba.ca/cgph
An International Conference Presented by the Gairdner Foundation and the University of Manitoba SPONSORSHIP OPPORTUNITIES THE UNIVERSITY OF MANITOBA AND GLOBAL HEALTH The Uof M has been a leader in global
More informationTUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE CONTROL OF A DUAL EPIDEMIC IN THE WHO AFRICAN REGION. Report of the Regional Director.
30 August 2007 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Fifty-seventh session Brazzaville, Republic of Congo, 27 31 August Provisional agenda item 7.8 TUBERCULOSIS AND HIV/AIDS: A STRATEGY FOR THE
More informationFollow-up to the high-level meetings of the United Nations General Assembly on health-related issues
EXECUTIVE BOARD EB44/ 44th session December 08 Provisional agenda item 5.8 Follow-up to the high-level meetings of the United Nations General Assembly on health-related issues Ending tuberculosis Report
More informationTBVAC2020. Advancing novel & promising TB vaccine candidates from discovery to preclinical/early clinical development
TBVAC2020 Advancing novel & promising TB vaccine candidates from discovery to preclinical/early clinical development Défis Scientifiques et Economiques du Développement de Vaccins pour les Pays du Sud
More informationStatement by Dr Marcos Espinal at the ECOSOC High-Level Segment, 6 July Madam President, Esteemed Delegates, Ladies and Gentlemen.
Statement by Dr Marcos Espinal at the ECOSOC High-Level Segment, 6 July 2009 Madam President, Esteemed Delegates, Ladies and Gentlemen. Many thanks for the opportunity to speak here today. I think the
More informationConfronting infectious diseases and the role of vaccination: A global perspective KATE ANTEYI. MD, MPH, MBA
Confronting infectious diseases and the role of vaccination: A global perspective KATE ANTEYI. MD, MPH, MBA Technical Advisor, United States Agency for International Development (USAID) Chair, WONCA Working
More information5 th Islamic Conference of Health Ministers. Resolution. Istanbul, Turkey November 2015 (5-7 Safar 1437H)
5 th Islamic Conference of Health Ministers Resolution Istanbul, Turkey 17-19 November 2015 (5-7 Safar 1437H) Draft Resolution No. 2/5-ICHM On Healthy Life Style, Prevention and Control of Communicable
More informationAntimicrobial resistance Fact sheet N 194 Updated April 2014
Antimicrobial resistance Fact sheet N 194 Updated April 2014 Key facts Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by
More informationJanuary 17, Re: Secretary s Advisory Committee on National Health Promotion and Disease Prevention Objectives for Healthy People 2030
January 17, 2019 Don Wright, MD, MPH, FAAFP Deputy Assistant Secretary for Health Office of Disease Prevention and Health Promotion Department of Health and Human Services Tower Building 1101 Wootton Parkway,
More informationCopenhagen, Denmark, September August Malaria
Regional Committee for Europe 64th session EUR/RC64/Inf.Doc./5 Copenhagen, Denmark, 15 18 September 2014 21 August 2014 140602 Provisional agenda item 3 ORIGINAL: ENGLISH Malaria Following the support
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I offer testimony in
Testimony of the Infectious Diseases Society of America (IDSA) on the Fiscal Year 2018 Department of Health and Human Services Budget Prepared for the U.S. House of Representatives Subcommittee on Labor-HHS-Education
More informationFast-Forwarding a Cure for Melanoma
Fast-Forwarding a Cure for Melanoma Vision Targeting an Urgent Problem Melanoma often starts out small, misleadingly insignificant a change in a mole, a mark on a fingernail. But the consequences can be
More informationA NEW FINANCING MODEL FOR THE SUSTAINABLE DEVELOPMENT ERA
A NEW FINANCING MODEL FOR THE SUSTAINABLE DEVELOPMENT ERA The Global Financing Facility in Support of Every Woman Every Child Photo by Maria Fleischmann WHY NOW? Photo by Dominic Chavez Countries have
More informationTowards a global HIV prevention coalition and road map. Preventing and reducing new HIV infections by 75% by 2020
Towards a global HIV prevention coalition and road map Preventing and reducing new HIV infections by 75% by 2020 Introduction United Nations Member States have committed to reducing new adult HIV infections
More informationProgress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa
SUMMARY REPORT Progress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa January December 2012 Table of contents List of acronyms 2 Introduction 3 Summary
More informationJapan's Role in Global Health and Human Security
Japan's Role in Global Health and Human Security Prof.Keizo TAKEMI Senior Fellow, Japan Center for Interantional Exchange, Research Fellow, Harvard School of Public Health Professor, Tokai University Why
More informationWorld Health Organization. A Sustainable Health Sector
World Health Organization A Sustainable Health Sector Response to HIV Global Health Sector Strategy for HIV/AIDS 2011-2015 (DRAFT OUTLINE FOR CONSULTATION) Version 2.1 15 July 2010 15 July 2010 1 GLOBAL
More informationBusiness Methods for Positive Global Health Impact
Business Methods for Positive Global Health Impact Gary M. Cohen Executive Vice President President, Global Health and Development BD IS ADDRESSING THE WORLD S LEADING HEALTH PROBLEMS THROUGH UNIQUE PUBLIC-PRIVATE
More informationCatalytic Framework to End AIDS, TB and Eliminate Malaria in Africa by 2030
Catalytic Framework to End AIDS, TB and Eliminate Malaria in Africa by 2030 Introduction The Catalytic Framework to End AIDS, TB and Eliminate Malaria in Africa by 2030 provides an overarching policy framework
More informationTheresa NeSmith Centers for Disease Control and Prevention Center for Global Health Division of Global HIV/AIDS International Laboratory Branch
Theresa NeSmith Centers for Disease Control and Prevention Center for Global Health Division of Global HIV/AIDS International Laboratory Branch PEPFAR Laboratory Program is a Critical Part of Health Systems
More informationUnderstanding the Economics of Microbial Threats A Workshop
Understanding the Economics of Microbial Threats A Workshop Abbreviated Statement of Task: Agenda JUNE 12-13, 2018 The National Academies Keck Building 500 Fifth Street NW - Room 100 Washington, DC 20001
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationBD-PEPFAR Labs for Life Partnership
BD-PEPFAR Labs for Life Partnership Renuka Gadde BD Global Health Jane Mwangi Division of Global HIV & TB, CDC Kenya FORUM ON PUBLIC-PRIVATE PARTNERSHIPS FOR GLOBAL HEALTH AND SAFETY October 27-28, 2016
More informationThe Value of Product Development Partnerships in Vaccine Innovation. Hansi J. Dean International AIDS Vaccine Initiative
The Value of Product Development Partnerships in Vaccine Innovation Hansi J. Dean International AIDS Vaccine Initiative The Product Development Partnership Model A non-profit partnership of public and
More informationGlobal health and vaccination: TB & beyond. Dr Mary Moran Executive Director
Global health and vaccination: TB & beyond Dr Mary Moran Executive Director mmoran@policycures.org Outline About Policy Cures 3 reasons to focus on vaccine innovation Where are we today? The pipeline Where
More informationGuidance on Matching Funds: Tuberculosis Finding the Missing People with TB
February 2017 Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB 1. Background TB is the leading cause of death by infectious disease, killing 1.8 million people in 2015. Each
More informationSPONSORSHIP OPPORTUNITIES JUNE 12-13, umanitoba.ca/cgph
An International Conference Presented by the Gairdner Foundation and the University of Manitoba SPONSORSHIP OPPORTUNITIES THE UNIVERSITY OF MANITOBA AND GLOBAL HEALTH The Uof M has been a leader in global
More informationRenewing Momentum in the fight against HIV/AIDS
2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly
More informationContextual overview with reference to MDG Goal 6 and projection for Post-2015
Contextual overview with reference to MDG Goal 6 and projection for Post-2015 10th Partnership Annual Conference Side Event Combating HIV and TB through a joint regional action Helsinki, Finland November
More informationFifth report of Committee A
SIXTY-EIGHTH WORLD HEALTH ASSEMBLY (Draft) A68/73 26 May 2015 Fifth report of Committee A (Draft) Committee A held its twelfth and thirteenth meetings on 25 May 2015 under the chairmanship of Dr Eduardo
More informationOPERATIONAL FRAMEWORK. for the Global Strategy for Women s, Children s and Adolescents Health
OPERATIONAL FRAMEWORK for the Global Strategy for Women s, Children s and Adolescents Health Every Woman Every Child 2016 OPERATIONAL FRAMEWORK for the Global Strategy for Women s, Children s and Adolescents
More informationExecutive Summary. Emergency meeting EBOLA Lessons learned from past Ebola outbreaks to inform current risk management. Dar es Salaam, Tanzania
Executive Summary Emergency meeting EBOLA Lessons learned from past Ebola outbreaks to inform current risk management Dar es Salaam, Tanzania 1st 2nd September 2014 London, Lyon, Dar, 7th September 2014
More informationAhimsa Roundtable Cape Town, South Africa June 2015
A partnership to save lives The critical role of faith-based organizations and faith-inspired communities in Global Health and the fight against AIDS, TB and malaria Ahimsa Roundtable Cape Town, South
More informationUpdate on TB Vaccines
Update on TB Vaccines Hennie Geldenhuys 11 May 2012 A safe and effective TB Vaccine within a decade A Strategic Blueprint for the Next Decade Tuberculosis, Vol 92, March 2012, Suppl. 1, pgs S1-S35 On
More informationVaccine Innovation and Adult Immunization Landscape
Vaccine Innovation and Adult Immunization Landscape National Adult and Influenza Immunization Summit, May 12-14, 2015 Phyllis Arthur Senior Director Vaccines, Immunotherapeutics & Diagnostics Policy parthur@bio.org
More informationMonitoring of the achievement of the health-related Millennium Development Goals
SIXTY-THIRD WORLD HEALTH ASSEMBLY WHA63.15 Agenda item 11.4 21 May 2010 Monitoring of the achievement of the health-related Millennium Development Goals The Sixty-third World Health Assembly, Having considered
More informationEmergency Plan. Pink Ribbon Red. under President. With. screened and Significantly. Commitments: to catalyze. a dynamic, including. of shared.
Pink Ribbon Red Ribbon Overview Pink Ribbon Red Ribbon is an innovative partnership to leverage public and private investments in global health to combat cervical and breast cancer two of the leading causes
More informationHep B United National Summit Report July 27-29, 2016 Washington, D.C.
Hep B United National Summit Report July 27-29, 2016 Washington, D.C. Introduction and Summit Goals The 4th Annual Hep B United National Summit was held in Washington, D.C. July 27-29, 2016, coinciding
More informationProgramme Time to end TB a new path to defeating the world s oldest epidemic Monday 19 Tuesday 20 June 2017 WP1550
Programme Time to end TB a new path to defeating the world s oldest epidemic Monday 19 Tuesday 20 June 2017 WP1550 Tuberculosis (TB) is humanity s greatest infectious killer. Seventy years since the discovery
More informationReadiness for Microbial Threats 2030: Exploring Lessons Learned since the 1918 Influenza Pandemic A Workshop
Readiness for Microbial Threats 2030: Exploring Lessons Learned since the 1918 Influenza Pandemic A Workshop Objectives: Agenda NOVEMBER 27-28, 2018 The National Academies Keck Building 500 Fifth Street
More informationALL LIVES HAVE EQUAL VALUE
ALL LIVES HAVE EQUAL VALUE Global Health Product Development Challenges and Opportunities IQ Symposium, Oct 5, 2016 Niya Bowers Senior Program Officer, CMC, Integrated Development 2015 Bill & Melinda Gates
More informationFISCAL YEAR 2020 APPROPRIATIONS REQUESTS (updated ) USAID Global Health Programs (GHP) and State Department
FISCAL YEAR 2020 APPROPRIATIONS REQUESTS (updated 2.13.19) Contact: Brian Massa, Senior Manager for Global Health Advocacy, Shot@Life (bmassa@unfoundation.org) USAID Global Health Programs (GHP) and State
More informationINVESTING IN A NEW FINANCING MODEL FOR THE SUSTAINABLE DEVELOPMENT ERA
Photo by Dominic Chavez INVESTING IN A NEW FINANCING MODEL FOR THE SUSTAINABLE DEVELOPMENT ERA Private Sector Engagement in the Global Financing Facility in Support of Every Woman Every Child 1 www.globalfinancingfacility.org
More informationMathematical modelling to accelerate development of new tuberculosis vaccines
Mathematical modelling to accelerate development of new tuberculosis vaccines Preliminary Results Rebecca Harris, Tom Sumner, Gwen Knight and Richard White 22 nd February 2018 Harris et al. 2016 Modelling
More informationThe Global Fund & UNICEF Partnership
The Global Fund & UNICEF Partnership Prof Michel D. Kazatchkine Executive Director UNICEF Executive Board February 9 th, 2011 The Global Fund Millennium Development Goals 1. Eradicate extreme poverty and
More informationThe Western Pacific Region faces significant
COMBATING COMMUNICABLE DISEASES A medical technician draws blood for HIV screening in Manila. AFP elimination of mother-to-child transmission of HIV and congenital syphilis was piloted in Malaysia and
More informationDesigned for Life A DECADE IN THE MAKING, LOW-COST INFANT HIV TEST NEARS CLINICAL USE
Kara Palamountain, executive director of the Kellogg School s Global Health Initiative, discusses the infant-hiv strip test with a group of healthcare workers in Africa. Photo courtesy Kara Palamountain
More informationPARALLEL SESSION 2.4
PARALLEL SESSION 2.4 CHANGING DYNAMICS: EMERGING INFECTIOUS DISEASES AND ANTIMICROBIAL RESISTANCE IN AN ERA OF EXPANDING GLOBAL HUMAN POPULATION GROWTH AND MOVEMENT BACKGROUND The global human population
More informationThe outlook for hundreds of thousands adolescents is bleak.
Adolescents & AIDS Dr. Chewe Luo Chief HIV/AIDS, UNICEF Associate Director, Programmes Division 28/11/17 Professor Father Micheal Kelly Annual Lecture on HIV/AIDS Dublin, Ireland The outlook for hundreds
More informationUC San Diego HIV Institute Creating a Future Without HIV/AIDS
UC San Diego HIV Institute Creating a Future Without HIV/AIDS Executive Summary HIV/AIDS will never cure itself, but at the University of California San Diego and UC San Diego Health, we believe that we
More informationWorking for an International Organization in Public-Private Partnership : The Global Fund to Fight AIDS, Tuberculosis and Malaria
Working for an International Organization in Public-Private Partnership : The Global Fund to Fight AIDS, Tuberculosis and Malaria Birgit Poniatowski Acting Manager, Board Relations Overview The Global
More information10.4 Advocacy, Communication and Social Mobilization Working Group: summary strategic plan,
10.4 Advocacy, Communication and Social Mobilization Working Group: summary strategic plan, 2006 2015 Introduction A significant scaling-up of advocacy, communication and social mobilization for TB will
More informationGlobal Collaboration on Cervical Cancer Prevention
Global Collaboration on Cervical Cancer Prevention Celina Schocken, JD, MBA, MPP Chief Executive Officer Presentation to the 2016 World Cancer Congress 1 November 2016 What Does Pink Ribbon Red Ribbon
More informationQuestions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs
Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs What causes TB? TB is caused by the bacterium Mycobacterium tuberculosis. Although it can cause disease in
More informationThe M8 Alliance Declaration. World Health Summit 2016 (Version: 07/10/ :30)
World Health Summit 2016 (Version: 07/10/2016-20:30) This year's World Health Summit (WHS) took place in a political context of great hope and serious alarm. Immense strides were made at the UN General
More informationDeveloping the next generation of infection and immunity leaders. The Peter Doherty Institute for Infection and Immunity
Developing the next generation of infection and immunity leaders The Peter Doherty Institute for Infection and Immunity Nobody can decide to discover something, but there are ways of making a discovery
More informationSanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines
Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines 1 Vaccines: the single most effective medical intervention 2 Vaccines save lives Millions of cases
More informationOperations Research to Advance Scale-Up of HIV/ AIDS Programmes: What is the Way Forward?
Operations Research to Advance Scale-Up of HIV/ AIDS Programmes: What is the Way Forward? Report of a special session convened by the International AIDS Society with support from the Doris Duke Charitable
More informationThe EU strategy in Horizon2020 to fight poverty related diseases
Meeting on EDCTP2 French Ministry of Education, Science and Innovation, Paris 30 June 2017 The EU strategy in Horizon2020 to fight poverty related diseases Line Matthiessen Acting Director Health Directorate
More informationThomas C. Wilmot, Sr. Judy Wilmot Linehan
Thomas C. Wilmot, Sr. Judy Wilmot Linehan The Wilmot Family For more than 35 years, the Wilmot family has been dedicated to supporting cancer research and care for the Rochester community. Their generosity
More informationOverview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015
Overview of the First Regional Dengue Symposium Rio de Janeiro, Brazil, 3-4 November 2015 Ana F. Carvalho, MBA, MPH Director, Special Projects Vaccine Advocacy and Education Presented by: Jacqueline Lim
More information2016/LSIF/FOR/002 Strengthening Surveillance for Antimicrobial Resistance and Healthcare-Associated Infections
2016/LSIF/FOR/002 Strengthening Surveillance for Antimicrobial Resistance and Healthcare-Associated Infections Submitted by: United States Policy Forum on Strengthening Surveillance and Laboratory Capacity
More informationIHI South Africa Quarterly Report
IHI South Africa Quarterly Report April 1 st -July 31 st 2010 Executive Summary The South African country programme was started by the Institute for Healthcare Improvement in 2005. Over the past five years,
More informationGlobal Governance for Health: Protecting Vulnerable People from Infectious Diseases in Countries with Weak Health System
2016 Australasian Aid Conference Global Governance for Health: Protecting Vulnerable People from Infectious Diseases in Countries with Weak Health System Yasushi KATSUMA, Ph.D. Dean & Professor, Graduate
More informationDEVELOPMENT. The European Union confronts HIV/AIDS, malaria and tuberculosis. A comprehensive strategy for the new millennium EUROPEAN COMMISSION
DEVELOPMENT The European Union confronts HIV/AIDS, malaria and tuberculosis A comprehensive strategy for the new millennium EUROPEAN COMMISSION DE 121 FEB 2004 A global challenge Every minute, 11 people
More informationViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV
ViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV ViiV Healthcare is a company 100% committed to HIV, and we are always looking to move beyond the status
More informationUniting the world against AIDS
Uniting the world against AIDS A letter from Peter Piot, Executive Director For over 27 years, our world has been living with HIV. And in just this short time, AIDS has become one of the make-or-break
More informationDEPARTMENT OF INTERNATIONAL HEALTH
DEPARTMENT OF INTERNATIONAL HEALTH he Health Systems Program is a global leader in research, teaching, and strategic collaborations focused on achieving accessible, costeffective health care and healthy
More informationCenter for Global Health. CDC Global Health Saving Lives Overseas, Protecting Americans at Home
Center for Global Health CDC Global Health Saving Lives Overseas, Protecting Americans at Home CDC Overview Part of the U.S. Department of Health and Human Services, CDC is the nation s leading public
More informationThe United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America
The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America Mike Segar / Reuters Executive Summary Context On 26 September 2018, the United Nations
More informationCHAIR: DR JORGE SAMPAIO, UN SECRETARY-GENERAL'S SPECIAL ENVOY TO STOP TB AND FORMER PRESIDENT OF THE PORTUGUESE REPUBLIC
PROVISIONAL AGENDA WEDNESDAY 1 APRIL 2009 SESSION 1: THE CHALLENGE OF M/XDR-TB: GLOBAL AND NATIONAL LEADERSHIP CHAIR: DR JORGE SAMPAIO, UN SECRETARY-GENERAL'S SPECIAL ENVOY TO STOP TB AND FORMER PRESIDENT
More informationSTRENGTHENING HEALTH SYSTEMS: TOWARD UNIVERSAL HEALTH COVERAGE & GLOBAL HEALTH SECURITY
STRENGTHENING HEALTH SYSTEMS: TOWARD UNIVERSAL HEALTH COVERAGE & GLOBAL HEALTH SECURITY APRIL 10, 2018 @GlobalHealthOrg #WHA71 WELCOME LOYCE PACE PRESIDENT & EXECUTIVE DIRECTOR GLOBAL HEALTH COUNCIL @GlobalHealthOrg
More informationTestimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and
Testimony of the Association for Professionals in Infection Control and Epidemiology (APIC) and The Society for Healthcare Epidemiology of America (SHEA) to the U.S. House of Representatives Appropriations
More informationDifferentiated Service Delivery: Taking Innovative Delivery Models to Scale
Differentiated Service Delivery: Taking Innovative Delivery Models to Scale Wafaa El-Sadr, MD, MPH, MPA ICAP at Columbia University Outline The Promise of Differentiated Service Delivery (DSD) Scale-up
More informationEcumenical Ebola Response
Dear readers, Welcome to the third edition of the newsletter. It is the first issue in 2015! The valuable role churches and faith communities play in addressing the current Ebola outbreak in West Africa
More informationGlobal HIV Vaccine Enterprise Strategic Plan
Global HIV Vaccine Enterprise Strategic Plan 2018-2023 Foreword For over a decade, the Global HIV Vaccine Enterprise (the Enterprise) has played a unique and essential role as a neutral convener and facilitator,
More informationChildhood Vaccination and Immunisation
DIRECTORATE GENERAL FOR INTERNAL POLICIES POLICY DEPARTMENT A: ECONOMIC AND SCIENTIFIC POLICY WORKSHOP Childhood Vaccination and Immunisation Brussels, 19 June 2013 MEETING DOCUMENT Policy Department A:
More information